OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Ondrej Venglár, Julio Rodriguez Bagó, Benjamin Motais, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 23
Ondrej Venglár, Julio Rodriguez Bagó, Benjamin Motais, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 23
Showing 23 citing articles:
Programmed Remodeling of the Tumor Milieu to Enhance NK Cell Immunotherapy Combined with Chemotherapy for Pancreatic Cancer
Xiaohu Yang, Chunyan Li, Hongchao Yang, et al.
Nano Letters (2024) Vol. 24, Iss. 11, pp. 3421-3431
Closed Access | Times Cited: 8
Xiaohu Yang, Chunyan Li, Hongchao Yang, et al.
Nano Letters (2024) Vol. 24, Iss. 11, pp. 3421-3431
Closed Access | Times Cited: 8
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Bisht, Taro Fukao, Marielle Chiron, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20332-20352
Open Access | Times Cited: 18
Kamlesh Bisht, Taro Fukao, Marielle Chiron, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20332-20352
Open Access | Times Cited: 18
Phenotypic Heterogeneity of Dysfunctional Natural Killer Cells During Chronic Infection or Cancer
Kévin Pouxvielh, Marie Marotel, Noëmi Rousseaux, et al.
Springer eBooks (2025), pp. 1-31
Closed Access
Kévin Pouxvielh, Marie Marotel, Noëmi Rousseaux, et al.
Springer eBooks (2025), pp. 1-31
Closed Access
Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies—Comparative Characterization of Current Protocols
Tatiana Budagova, Anna Efremova, Natalia Usman, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1107-1107
Open Access
Tatiana Budagova, Anna Efremova, Natalia Usman, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1107-1107
Open Access
Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
Tomonori Iyoda, Satoru Yamasaki, Shogo Ueda, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 348-348
Open Access | Times Cited: 12
Tomonori Iyoda, Satoru Yamasaki, Shogo Ueda, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 348-348
Open Access | Times Cited: 12
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
Danilo De Novellis, Raffaele Fontana, Valentina Giudice, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 645-645
Open Access | Times Cited: 18
Danilo De Novellis, Raffaele Fontana, Valentina Giudice, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 645-645
Open Access | Times Cited: 18
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications
Mengping Chen, Jinxing Jiang, Jian Hou
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 10
Mengping Chen, Jinxing Jiang, Jian Hou
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 10
Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis
Qing-Ming Wang, Guang‐Yu Lian, Su-Mei Sheng, et al.
Molecular Cancer Research (2023) Vol. 22, Iss. 2, pp. 125-136
Closed Access | Times Cited: 9
Qing-Ming Wang, Guang‐Yu Lian, Su-Mei Sheng, et al.
Molecular Cancer Research (2023) Vol. 22, Iss. 2, pp. 125-136
Closed Access | Times Cited: 9
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Rafael Alonso Fernández, Jessica Encinas, Laetitia Pierre-Louis, et al.
Blood Advances (2022) Vol. 7, Iss. 1, pp. 9-19
Open Access | Times Cited: 15
Rafael Alonso Fernández, Jessica Encinas, Laetitia Pierre-Louis, et al.
Blood Advances (2022) Vol. 7, Iss. 1, pp. 9-19
Open Access | Times Cited: 15
Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators—a review
Alexandra-Ligia Dincă, Adriana Diaconu, Rodica Bîrlă, et al.
International Journal of Immunopathology and Pharmacology (2023) Vol. 37
Open Access | Times Cited: 8
Alexandra-Ligia Dincă, Adriana Diaconu, Rodica Bîrlă, et al.
International Journal of Immunopathology and Pharmacology (2023) Vol. 37
Open Access | Times Cited: 8
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
Sara Piccinelli, Rizwan Romee, Roman M. Shapiro
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 42-51
Closed Access | Times Cited: 5
Sara Piccinelli, Rizwan Romee, Roman M. Shapiro
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 42-51
Closed Access | Times Cited: 5
Inhibition of MICA and MICB shedding enhances memory-like NK cell-mediated cytotoxicity against multiple myeloma
Sabrin Tahri, Sara Piccinelli, Nang Kham Su, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5365-5370
Open Access | Times Cited: 1
Sabrin Tahri, Sara Piccinelli, Nang Kham Su, et al.
Blood Advances (2024) Vol. 8, Iss. 20, pp. 5365-5370
Open Access | Times Cited: 1
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
Sara Petillo, E. Sproviero, Luisa Loconte, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 4
Sara Petillo, E. Sproviero, Luisa Loconte, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 4
Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells
Avishay Edri, Nimrod Ben-Haim, Astar Hailu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17231-17231
Open Access | Times Cited: 3
Avishay Edri, Nimrod Ben-Haim, Astar Hailu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17231-17231
Open Access | Times Cited: 3
Circulating immune cells and multiple myeloma: A mendelian randomization study
Zexin Zhang, Gulizeba Muhetaer, Zhikai Xiahou, et al.
Research Square (Research Square) (2024)
Open Access
Zexin Zhang, Gulizeba Muhetaer, Zhikai Xiahou, et al.
Research Square (Research Square) (2024)
Open Access
Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma
Jun-Ting Lv, Yu-Tian Jiao, Xinle Han, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e30123-e30123
Open Access
Jun-Ting Lv, Yu-Tian Jiao, Xinle Han, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e30123-e30123
Open Access
Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity
Xin Chen, Liwen Wang, Qian Cheng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 8, pp. 167457-167457
Open Access
Xin Chen, Liwen Wang, Qian Cheng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 8, pp. 167457-167457
Open Access
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Kamlesh Bisht, Aimee Merino, Rob Igarashi, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access
Kamlesh Bisht, Aimee Merino, Rob Igarashi, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access
Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma
Z J Li, Huihan Zhao, Zhongqing Li, et al.
Medicine (2024) Vol. 103, Iss. 48, pp. e40710-e40710
Open Access
Z J Li, Huihan Zhao, Zhongqing Li, et al.
Medicine (2024) Vol. 103, Iss. 48, pp. e40710-e40710
Open Access
Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms
İstemi Serin, Yasin Colak, Yasemin Oyacı, et al.
Cytokine (2023) Vol. 172, pp. 156401-156401
Closed Access | Times Cited: 1
İstemi Serin, Yasin Colak, Yasemin Oyacı, et al.
Cytokine (2023) Vol. 172, pp. 156401-156401
Closed Access | Times Cited: 1
Overexpression of VEGF in the MOPC 315 Plasmacytoma Induces Tumor Immunity in Mice
Byung‐Gyu Kim, Sung Hee Choi, John J. Letterio, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5235-5235
Open Access | Times Cited: 2
Byung‐Gyu Kim, Sung Hee Choi, John J. Letterio, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5235-5235
Open Access | Times Cited: 2
Natural killer cells and bone marrow mesenchymal stem cells: A dangerous liaison in multiple myeloma
Iria Fernandez Botana, Etienne Moussay, Jérôme Paggetti
Clinical and Translational Discovery (2022) Vol. 2, Iss. 3
Open Access
Iria Fernandez Botana, Etienne Moussay, Jérôme Paggetti
Clinical and Translational Discovery (2022) Vol. 2, Iss. 3
Open Access
